Lowdell Mark William's Form 4 filing
Inmune Bio, Inc. (INMB) · filed Jul 9, 2021
- Accession no.
- 0001213900-21-036355
- Filed
- Jul 9, 2021
- Trade date
- Jul 7-8, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $604.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lowdell Mark WilliamCIK 0001767037 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $20.00 to $20.04, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $20.00 to $20.48, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.
Referenced by the price of 1 transaction in Table I.